Ionis Pharmaceuticals, Inc.
NASDAQ:IONSBiotechnology
+$1.22 today
- Market cap
- $4.56B
- Beta
- 0.37
- P/E (TTM)
- -37.5
- EPS (TTM)
- -$1.98
Volume 3.23M
Average 1.83M
IONS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ionis Pharmaceuticals, Inc.NASDAQ: IONS
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development dips below year-ago levels
Q3 FY2026 research & development of $215.88M fell 0.9% year over year, behind the +4.7% change in trailing-twelve-month research & development. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.
Context
- Research & development amounted to 97.0% of revenue in FY2025, down 30.8 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -0.9% toward the trailing-twelve-month pace of +4.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 916M USD
- Year-over-year change
- +1.6%
- 4-year CAGR
- +9.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 916M | +1.6% |
| FY2024 | 2024-12-31 | 901.53M | +0.2% |
| FY2023 | 2023-12-31 | 899.63M | +8.0% |
| FY2022 | 2022-12-31 | 833M | +29.5% |
| FY2021 | 2021-12-31 | 643M | — |
Research & Development vs competitors
How IONS compares with its peers on the latest reported figures
- IONS's LTM Sep 2026 research & development of $923.16M is the 4th highest of the 9 companies compared; the peer median is $836.76M.
- Its year-over-year change of +4.7% is the 5th highest of 9, against a peer median of -1.3%.
- Research & development amounts to 96.2% of revenue for IONS, versus a peer median of 42.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $181.1B | +19955.1% | +12.4% | 17.6% | |
| LTM Jun 2026 | $1.95B | -19.9% | -9.0% | 19.6% | |
| LTM Jun 2026 | $1.51B | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $530.96M | +12.1% | +6.1% | 74.5% | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| Peer median (excluding IONS) | $836.76M | -1.3% | +4.1% | 42.1% | |
Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 810.46M | 587.37M | 787.65M | 705.14M | 944M |
| Cost of Revenue | 10.84M | 14.12M | 9.13M | 11.22M | 16M |
| Gross Profit | 799.61M | 573.25M | 778.51M | 693.92M | 928M |
| Gross Margin | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% |
| Research & Development | 643M | 833M | 899.63M | 901.53M | 916M |
| Selling, General & Admin | 170.9M | 150.3M | 232.6M | 267.5M | 394M |
| Operating Expenses | 829.8M | 983.44M | 1.13B | 1.17B | 1.31B |
| Depreciation & Amortization | 19.56M | 22.11M | 22.5M | 21.99M | 22.69M |
| EBITDA | (5.19M) | (227.76M) | (235.87M) | (353.72M) | (284.31M) |
| EBITDA Margin | -0.6% | -38.8% | -29.9% | -50.2% | -30.1% |
| Operating Income | (30.19M) | (410.19M) | (353.73M) | (475.08M) | (382M) |
| Operating Margin | -3.7% | -69.8% | -44.9% | -67.4% | -40.5% |
| Interest Income | 10.04M | 25.33M | 89.04M | 107.02M | 97.77M |
| Interest Expense | 9.35M | 8.12M | 81.46M | 90.45M | 90.54M |
| Other Income / Expenses | 1.04M | 152.21M | 19.77M | 15.01M | 2M |
| Income Before Tax | (29.15M) | (257.99M) | (333.97M) | (460.07M) | (380M) |
| Pre-Tax Margin | -3.6% | -43.9% | -42.4% | -65.2% | -40.3% |
| Income Tax Expense | (551K) | 11.74M | 32.32M | (6.17M) | 1M |
| Net Income | (28.6M) | (269.72M) | (366.29M) | (453.9M) | (381M) |
| Net Margin | -3.5% | -45.9% | -46.5% | -64.4% | -40.4% |
| EPS (Basic) | (0.20) | (1.90) | (2.56) | (3.04) | (2.38) |
| EPS (Diluted) | (0.20) | (1.90) | (2.56) | (3.04) | (2.38) |
| Weighted Avg Shares | 141.02M | 141.85M | 143M | 149.51M | 160M |
| Weighted Avg Shares (Diluted) | 141.02M | 141.85M | 143.19M | 149.51M | 160M |
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
Intrinsic Alpha fair value
Locked
Current Price
$27.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.